Prostate Cancer - Pipeline Review, H2 2014


Naperville, IL -- (SBWIRE) -- 10/16/2014 -- Reportstack, provider of premium market research reports announces the addition of Prostate Cancer - Pipeline Review, H2 2014 market report to its offering

Prostate Cancer - Pipeline Review, H2 2014, provides an overview of the Prostate Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects.

report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Prostate Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Prostate Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Prostate Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Baxter International Inc.
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
GlaxoSmithKline plc
Bioniche Life Sciences, Inc.
Genentech, Inc.
Bavarian Nordic A/S
Isis Pharmaceuticals, Inc.
Daiichi Sankyo Company, Limited
Merck & Co., Inc.
Emergent BioSolutions Inc.
Oxford BioMedica plc
Takeda Pharmaceutical Company Limited
Amorfix Life Sciences Ltd.
Ipsen S.A.
MediGene AG
Bio-Path Holdings, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Samyang Holdings Corporation
Aphios Corporation
Astellas Pharma Inc.
GTx, Inc.
Ono Pharmaceutical Co., Ltd.
Orion Corp
Pfizer Inc.
Astex Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Genmab A/S
Progenics Pharmaceuticals, Inc.
Exelixis, Inc.
Aduro BioTech, Inc.
A. Menarini Industrie Farmaceutiche Riunite Srl
Ferring International Center S.A.
Celgene Corporation
Onyx Pharmaceuticals, Inc.
Bayer AG
AntiCancer, Inc.
Merck KGaA
Advaxis, Inc.
Alchemia Limited
Harbor Therapeutics, Inc.
Celldex Therapeutics, Inc.
Anavex Life Sciences Corp.
ValiRx Plc
Active Biotech AB
AEterna Zentaris Inc.
Immunomedics, Inc.
Antisense Therapeutics Limited
Arrowhead Research Corporation
Lorus Therapeutics Inc.
MEI Pharma, Inc.
Bionomics Limited
Northwest Biotherapeutics, Inc.
Novogen Limited
Nymox Pharmaceutical Corporation
Oncolytics Biotech Inc.
Oncothyreon Inc.
Compugen Ltd.
Patrys Limited
Medivation, Inc.
ArQule, Inc.
Regeneron Pharmaceuticals, Inc.
Oncogenex Pharmaceuticals, Inc.
ProMetic Life Sciences Inc.
Galectin Therapeutics, Inc.
AnGes MG, Inc.
Quest PharmaTech Inc.
Synta Pharmaceuticals Corp.
Natco Pharma Limited
Sareum Holdings plc
Oasmia Pharmaceutical AB
DiaMedica Inc.
Dongkook Pharmaceutical Co., Ltd.
Galena Biopharma, Inc.
Hybrigenics S.A.
Rexahn Pharmaceuticals, Inc.
Merrion Pharmaceuticals Plc
Solasia Pharma K.K.
Fujifilm Corporation
Antigen Express, Inc.
Affitech A/S
Isarna Therapeutics GmbH
Colby Pharmaceutical Company
Mayne Pharma Group Limited
Chipscreen Biosciences Ltd
Supratek Pharma Inc.
Camurus AB
Fusion Antibodies Ltd
Actinium Pharmaceuticals, Inc.
CellCentric Ltd.
Med Discovery SA
Pro-Cure Therapeutics Limited
immatics biotechnologies GmbH
Vaxon Biotech
Advantagene, Inc.
CureVac GmbH
Medeia Therapeutics Ltd.
Aileron Therapeutics, Inc.
Alethia Biotherapeutics Inc.
GenSpera, Inc.
Ascenta Therapeutics, Inc.
Tokai Pharmaceuticals, Inc.
Coronado Biosciences, Inc.
MacroGenics, Inc.
Provenance Biopharmaceuticals Corp.
Antyra, Inc.
Ambrx, Inc.
Arno Therapeutics, Inc.
Orphagen Pharmaceuticals, Inc.
Pantarhei Bioscience BV
Azaya Therapeutics Incorporated
Semafore Pharmaceuticals, Inc.
GP Pharm, S.A.
IC-MedTech, Inc.
Innate Therapeutics Limited
ProNAi Therapeutics, Inc.
Angion Biomedica Corp.
Axelar AB
Endocyte, Inc.
Omnitura Therapeutics Inc.
AndroScience Corporation
Pharminox Limited
Immutep S.A.
Esperance Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
Omeros Corporation
TransTech Pharma, Inc.
Immunovaccine, Inc.
Peptron, Inc.
Enceladus Pharmaceuticals BV
BIND Therapeutics, Inc.
NewLink Genetics Corporation
Cellceutix Corporation
IGF Oncology, LLC.
TVAX Biomedical, Inc.
Quintessence Biosciences, Inc.
Bellicum Pharmaceuticals, Inc.
AB Science
Aprea AB
Kinex Pharmaceuticals, LLC
Biokine Therapeutics Ltd.
Adamis Pharmaceuticals Corporation
CureTech Ltd.
Cylene Pharmaceuticals, Inc.
Genelux Corporation
WntResearch AB
Viventia Biotechnologies Inc.
IRX Therapeutics, Inc.
Vicus Therapeutics, LLC
Oncovir, Inc.
TRACON Pharmaceuticals, Inc.
EndoCeutics, Inc.
Dompe Farmaceutici S.p.A.
Advanced Cancer Therapeutics
Viamet Pharmaceuticals, Inc.
3-V Biosciences, Inc.
Soricimed Biopharma Inc.
Almac Discovery Ltd.
VaxOnco Inc
BHR Pharma, LLC
KAEL-GemVax Co., Ltd.
Beta Pharma, Inc.
iCeutica, Inc.
Incuron, LLC
Ausio Pharmaceuticals, LLC
Errant Gene Therapeutics, LLC
Mebiopharm Co., Ltd.
Polaris Group
Vaccibody AS
Serometrix, LLC
CytoVac A/S
Miami VA Healthcare System
Acino Pharma AG
Bio-Cancer Treatment International Limited
Karyopharm Therapeutics, Inc.
Tesaro, Inc.
APIM Therapeutics AS
EntreChem, S.L.
Cold Genesys, Inc.
Zensun (Shanghai) Sci & Tech Co., Ltd.
Polyplus-transfection SA
Kancera AB
Vaxeal Holding SA
Arrien Pharmaceuticals, LLC
Qu Biologics Inc.
CZ BioMed Corp
Evgen Limited
Activartis Biotech GmbH
Panacela Labs, Inc.
Io Therapeutics, Inc.
Avipep Pty Ltd
Tactic Pharma, LLC
Kadmon Corporation, LLC
RAPID Pharmaceuticals AG
Akshaya Bio Inc.
ADC Therapeutics Sarl
Foresee Pharmaceuticals, LLC
Antoxis Limited
Tolero Pharmaceuticals, Inc.
iTeos Therapeutics SA
DexTech Medical AB
Armour Therapeutics Inc.
AbbVie Inc.
OncoNOx ApS
Curadis GmbH
Medvio Eurasia
PSites Pharma GmbH
Pharmedartis GmbH
DormaTarg, Inc.
Oncology Research International Limited
Biscayne Pharmaceuticals, Inc.
Sotio a.s.
Galileo Research s.r.l.
Vasgen Limited
Balonco GMBH
SillaJen Co. Ltd.
Bionature E.A. Ltd.

Complete report is available @

Roger Campbell
United States
Ph: 888-789-6604